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Summary
 
Infection of C57BL/6 mice with lymphocytic choriomeningitis virus (LCMV) stimulates ma-
jor histocompatibility complex class I–restricted cytotoxic T cells (CTLs), which normally re-
solve the infection. Three peptide epitopes derived from LCMV have been shown to bind the
mouse class I molecule H-2 D
 
b
 
 and to stimulate CTL responses in LCMV-infected mice. This
report describes the identity and abundance of each CTL epitope after their elution from
LCMV-infected cells. Based on this information, peptide abundance was found to correlate
with the magnitude of each CTL response generated after infection with LCMV. Subsequent
experiments, performed to determine the antiviral capacity of each CTL specificity, indicate
that the quantitative hierarchy of CTL activity does not correlate with the ability to protect
against LCMV infection. This report, therefore, indicates that immunodominant epitopes
should be defined, not only by the strength of the CTL response that they stimulate, but also
by the ability of the CTLs to protect against infection.
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T
 
hrough lysis of cells infected with viruses or other in-
tracellular pathogens, CTLs play an essential role in
the control of infections. Recognition of infected cells by
CTLs is mediated by MHC class I molecules, which be-
have as receptors for peptides derived from cytoplasmic
proteins (1, 2). Generation of peptide epitopes occurs by
proteolysis of cytoplasmic proteins by the 20S proteosome
(3), and it is likely that the overall spectrum of peptide
products generated in this way is influenced by the specific-
ity of this proteolytic unit. The specificity of the proteo-
some is thought to be further enhanced by IFN-
 
g
 
, which
mediates the substitution of certain housekeeping subunits
by MHC-encoded subunits that are thought to favor the
generation of class I–binding peptides (4–8). After protein
degradation, the resulting peptides are transported into the
lumen of the endoplasmic reticulum (ER)
 
1
 
 by the Tap
molecule (9–13). Since the Tap molecule has been shown
to transport peptides of different lengths and amino acid
compositions with different efficiencies (14), it is likely that
this molecule also imposes a selection on the spectrum of
peptides that reach the ER. On arrival in the ER, peptides
may bind to nascent class I molecules that mature as they
traffic through the Golgi to the cell surface. The rules that
govern peptide binding to class I molecules reflect comple-
mentarity between the structure of the 
 
a
 
1 and 
 
a
 
2 domains
of the class I molecule and the presence of certain key
amino acids within the peptide, which behave as anchor
residues (15–19). Sequencing of MHC-eluted peptides,
which predicted the anchor pocket interactions, elucidated
numerous class I allele-specific amino acid motifs that have
proven to be extremely useful in the search for peptide
epitopes (20–22). Therefore, it is clear that peptide epitopes
that are ultimately presented on the cell surface are selected
by the antigen processing pathway and by the class I mole-
cules to which they bind. Although the number of class
I–peptide complexes required to stimulate naive CTLs to
proliferate and become effector cells remains unknown, ev-
idence does exist that suggests that the magnitude of a
given CTL response is influenced by the abundance of an-
tigen on the cell surface.
CTL responses to three H-2
 
b
 
 (D
 
b
 
)-restricted CTL
epitopes have been identified in lymphocytic choriomenin-
gitis virus (LCMV)-infected C57BL/6 (B6) mice. The pu-
tative optimal sequences representing each epitope have
thus far been determined by measuring the efficiency of
peptide binding to H-2 D
 
b
 
 and by measuring CTL killing
 
1
 
Abbreviations used in this paper:
 
 ER, endoplasmic reticulum; GP, glyco-
protein; L, ligand; LCMV, lymphocytic choriomeningitis virus; NP, nu-
cleoprotein.
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of target cells pulsed with decreasing concentrations of
peptide. Two of these epitopes derive from the viral glyco-
protein ([GP]33-41 and GP276-286), whereas one has
been identified in the viral nucleoprotein ([NP]396-404;
references 23–28). In this study we confirm, after the elu-
tion of H-2 D
 
b
 
–binding peptides from LCMV-infected
cells, the precise identity of the CTL epitopes and deter-
mine their relative abundance in LCMV-infected cells. We
have examined the relationship between antigen abun-
dance and the magnitude of each peptide-specific CTL re-
sponse stimulated after infection with LCMV as well as the
relationship between antigen abundance and the capacity of
CTLs of each peptide specificity to protect against LCMV
infection.
 
Materials and Methods
 
Mice.
 
C57BL/6 (H-2
 
b
 
), wild-type 129 (H-2
 
b
 
), and IFN-
 
g
 
R–
deficient (IFN-
 
g
 
R
 
2/2
 
) mice (G129, H-2
 
b
 
) were obtained from
the Institut für Zuchthygiene (Tierspital Zürich, Zürich, Switzer-
land). All mice were kept in a specific pathogen–free mouse
house facility. The generation of IFN-
 
g
 
R
 
2/2
 
 mice has been de-
scribed previously (29).
 
Peptides.
 
The LCMV peptides NP396-404, GP276-286, and
GP33-41 were purchased from Neosystem Laboratoire (Stras-
burg, France).
 
Virus.
 
The LCMV-WE strain was originally obtained from
Dr. F. Lehmann-Grube (Hamburg, Germany) and was grown us-
ing L929 fibroblast cells (30). The nucleotide sequence of
LCMV-WE has been described previously (31).
 
Cells and Media.
 
Cultures of the methylcholantrene-induced
mouse fibroblast line MC57 (H-2
 
b
 
) were maintained in MEM.
Cultures of the human Tap-defective cell line T2 (32) transfected
with D
 
b
 
 and the Rauscher virus–transformed mouse T cell line
RMA-S, which has a defective Tap-2 gene (33), were maintained
in RPMI. Media were supplemented with 5 and 10% fetal calf se-
rum, respectively, penicillin-streptomycin, and L-glutamine.
 
Detection of Virus-specific Cytotoxic T Cells.
 
Spleen cell suspen-
sions were prepared from mice infected intravenously with 200
PFU LCMV or 2 
 
3 
 
10
 
6
 
 PFU recombinant vaccinia viruses at the
indicated time points. Cells were plated at 4 
 
3 
 
10
 
6
 
 cells/well (24-
well plate) in 1 ml of IMDM supplemented with 10% fetal calf
serum, penicillin-streptomycin, and 2-ME. The cultures were
supplemented with 1 ml of LCMV-infected, irradiated (2,000
rads) macrophages at a concentration of 2 
 
3 
 
10
 
5
 
/ml. Macrophages
were recovered from peritoneal washes of B6 mice that had been
infected 4 d before with 200 PFU LCMV and 6 d before with 2
ml thioglycollate. The spleen cells were cultured in the presence
of 10% Con A–induced rat spleen cell supernatant. After 5 d of
culture, restimulated spleen cells were resuspended in 0.7 ml of me-
dium/culture well and threefold dilutions of the effector cells
were performed (referred to as dilution of culture). Cytotoxicity
assays were carried out as described previously (34, 35). The tar-
get cells used were either MC57 cells that had been infected by
incubation with 0.1 PFU LCMV/cell 48 h before the experiment
or T2-D
 
b
 
 pulsed with the indicated concentrations of peptide.
For detection of ex vivo CTL activity, spleen cell suspensions
from mice infected intravenously with 200 PFU LCMV 8 d be-
fore testing were prepared in complete MEM and used directly in
cytotoxicity assays. For testing peptide fractions obtained by
HPLC separation, synthetic and natural peptides were titrated and
incubated with 10
 
4
 
 
 
51
 
Cr-labeled T2-D
 
b
 
 cells for 90 min at 37
 
8
 
C.
CTL lines were added at an effector/target ratio of 10:1 and the
cultures were incubated for a further 5 h before 100-
 
m
 
l superna-
tants were harvested and radioactivity was measured in a beta
counter. Specific lysis was determined as described previously.
 
Generation of Polyclonal CTL Lines.
 
Spleen cell suspensions were
prepared from mice that had been infected intravenously with
200 PFU LCMV-WE at least 3 mo previously. Cells were plated
at 4 
 
3 
 
10
 
6
 
 cells/well (24-well plate) in 1 ml IMDM/well supple-
mented with 10% fetal calf serum, penicillin-streptomycin, 2-ME,
and 10% Con A supernatant. The cultures were supplemented
with 1 ml of peptide-pulsed irradiated T2-D
 
b
 
 cells at a concentra-
tion of 4 
 
3 
 
10
 
5
 
/ml. Before irradiation, T2-D
 
b
 
 cells were incu-
bated with 100 
 
m
 
l of peptide at a concentration of 10 ng/ml for 1 h
at 37
 
8
 
C before extensive washing to remove any unbound pep-
tide. Cultures were restimulated at 10-d intervals using irradiated
peptide-pulsed T2-D
 
b
 
 cells as APCs at a responder/APC ratio of
10:1. These CTL lines were found to be of a single specificity af-
ter three rounds of restimulation.
 
Virus Infections.
 
MC57 cells were grown in triple layer tissue
culture flasks to near confluent density. Subsequently, cells were
infected by incubation with 0.1 PFU LCMV/cell and incubated
for a further 48 h. After trypsinization, the cells were spun down
and the pellets were stored at 
 
2
 
70
 
8
 
C. Success of infection was
monitored by staining for cell-surface expression of the LCMV-
GP using the mAb KL25 (36). KL25 staining was detected using
goat anti–mouse IgG1-FITC and analyzed by flow cytometry.
 
Extraction of Viral Peptides from Infected Cells.
 
10
 
9
 
 virus-infected
and uninfected cells were resuspended in 20 ml lysis buffer (PBS
 
1
 
 1% NP-40, 0.1 mM PMSF, 2 
 
m
 
g/ml leupeptin, 2 
 
m
 
g/ml aproti-
nin, and 0.0002% [wt/vol] pepstatin) and disrupted using a hand-
held glass homogenizer and sonication. The suspensions were
stirred at 4
 
8
 
C for 1 h before centrifugation at 4,000 rpm for 10
min. The supernatants were transferred to new tubes and spun in
an ultracentrifuge at 40,000 rpm for 1 h. After ultracentrifugation,
the supernatants were passed through prefilters before loading onto
glycine-coupled cyanogen bromide–activated Sepharose 4B columns
as a preclearing step. The D
 
b
 
 complexes were then purified by im-
munoaffinity chromatography using mAb B22.249 coupled to cyan-
ogen bromide-activated Sepharose 4B. After elution of the D
 
b
 
 com-
plexes using 0.1% TFA (pH 2), the eluted material was transferred
to a Centricon 10 and centrifuged at 3,000 rpm for 30 min. Material
 
,
 
10 kD was concentrated to 1 ml by vacuum centrifugation.
 
Fractionation by HPLC.
 
Peptide separations were carried out
on a reversed-phase prepacked column ([
 
m
 
RPC] C2/C18, 2.1 
 
3
 
100 mm; Pharmacia LKB, Piscataway, NJ) using the Pharmacia
LKB SMART system. Samples were injected in a volume of 500 
 
m
 
l.
The following elution procedure was used: solvent A, 0.1% TFA
in H
 
2
 
O; solvent B, 0.081% TFA in 80% acetonitrile; 0–5 min,
100% A; 5–10 min, 2%/min increase to 10% B; 10–15 min, con-
stant 10% B; 15–55 min, 0.75%/ml increase to 40% B; 55–65
min, 2%/min increase to 60% B; and 65–70 min, 3%/min in-
crease to 75% B. Flow rate was 150 
 
m
 
l/min. Fractions were col-
lected by peak fractionation and elution was monitored by mea-
suring UV light absorption at 214 nm in a continuous flow
detector. Acetonitrile was removed from eluted material by vac-
uum centrifugation before samples were made up to a standard
volume of 250 
 
m
 
l using PBS and stored at 
 
2
 
70
 
8
 
C. Fractions con-
taining peptide GP33-41 were supplemented with dithiothreitol
(DTT) to a final concentration of 0.01 mM to prevent dimeriza-
tion of the peptide via disulphide bond formation at the COOH-
terminal cysteine residue.
 
Protection Assays and Virus Titration.
 
Mice were infected in- 
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travenously with 20 PFU LCMV and reinjected intravenously 5 h
or 3 d later with the indicated numbers of peptide-specific CTL
lines. Virus titers were assessed in spleens 4 d later. LCMV titers
in spleens were determined as previously described (37).
 
Flow Cytometry.
 
For detection of cell-surface markers CD44,
CD25, CD69, and CD62 ligand (CD62L), CTL lines were incu-
bated on ice with FITC-labeled anti-CD8 and biotinylated anti-
CD44, -CD25, -CD69, and -CD62L antibodies (PharMingen,
San Diego, CA). The cells were subsequently incubated with
streptavidin-PE. After washing, the stained cells were resus-
pended in PBS containing 2% FCS and 0.5 mM EDTA (PBS/
FCS/EDTA), and analyzed by FACS
 
Ò
 
 (Becton Dickinson,
Mountain View, CA) using Cellquest software (Becton Dickinson).
Intracellular cytokine staining was carried out using CTLs that
had been incubated at 37
 
8
 
C overnight with LCMV-WE–infected
peritoneal macrophages at a macrophage/T cell ratio of 2:1. The
next day, the cells were incubated for a further 2 h in the pres-
ence of 2 
 
m
 
M monensin. After washing with PBS/FCS/EDTA,
the cells were stained as described above using tricolor-conju-
gated anti-CD8 antibodies. Subsequently, the cells were fixed in
100 
 
m
 
l PBS containing 2% (wt/vol) paraformaldehyde and per-
meabilized using PBS containing 1% FCS, 0.1% (wt/vol) sodium
azide, and 0.1% (wt/vol) saponin (permeabilization buffer). Per-
meabilized cells were stained with FITC-conjugated anti–IFN-
 
g
 
antibodies. The stained cells were washed twice in permeabiliza-
tion buffer, resuspended in PBS/FCS/EDTA, and analyzed by
FACS
 
Ò
 
. In all cases, spleen cells from naive B6 mice were used as
negative controls.
 
Results
 
CTL Responses to Epitopes GP33-41, GP276-286, and
NP396-404.
 
To determine the relative hierarchy of CTL
activity against epitopes GP33, GP276, and NP396, B6
mice were infected intravenously with 200 PFU of LCMV,
and cytotoxicity was measured at two different time points.
First, CTL activity was measured in direct ex vivo assays 8 d
after infection with LCMV. Second, CTL activity was
measured after in vitro restimulation of spleen cells isolated
from memory mice that had been infected at least 1 mo
previously with LCMV. As shown in Fig. 1, 
 
A
 
 and 
 
B
 
, CTL
responses where target cells were pulsed with 10 ng of each
peptide were strongest against those pulsed with GP33 fol-
lowed by NP396 and then GP276. Thus, values of specific
lysis obtained using bulk cultures correlate well with the es-
timated CTL precursor frequencies that have been calcu-
lated in LCMV-immune mice (data not shown). Lysis of
target cells pulsed with titrated concentrations of each pep-
tide was also measured using the same effector cells as de-
scribed above. The results, shown in Fig. 1, 
 
C
 
 and 
 
D
 
, indi-
cate that NP396-specific CTLs recognize peptide-pulsed
target cells 10–1,000 times more efficiently than CTLs spe-
cific for peptides GP276 and GP33, respectively. Poly-
clonal CTL lines specific for each peptide epitope were set
up using spleen cells from mice that had been infected at
least 3 mo before with LCMV. After three rounds of re-
stimulation using peptide-pulsed T2-D
 
b
 
 cells, all cells were
found to be CD8
 
1
 
 
 
and of a single specificity.
 
HPLC of Natural and Synthetic Peptides.
 
To ascertain the
identity of the natural D
 
b
 
-restricted LCMV peptides, natu-
rally processed peptides were eluted from D
 
b
 
 molecules pu-
rified from both LCMV-infected and uninfected MC57
cells. Eluted peptides were separated by reversed-phase
HPLC as described previously (38, 39). Each fraction was
made up to a final volume of 250 
 
m
 
l, and between 0.1 and
10% of each fraction was used to pulse chromium-labeled
T2-D
 
b
 
 cells. Fractions containing active peptides were
identified using polyclonal CTL lines specific for GP33-41,
Figure 1. Recognition of Db-restricted peptides by LCMV-specific
CTLs. Spleen cells were isolated from B6 mice at day 8 after infection (A
and C) and tested for cytotoxicity against unpulsed T2-Db cells (open trian-
gles) or T2-Db cells pulsed with peptides GP33 (open circles), GP276 (closed
triangles), and NP396 (closed circles). Cytotoxicity against the same target
cells was tested using spleen cells isolated from LCMV-immune mice that
were restimulated in vitro using LCMV-infected peritoneal macrophages
(B and D). CTL assays shown in C were carried out at an effector/target
ratio of 90:1, whereas assays shown in D were carried out at an effector/
target ratio of 20:1. 
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NP396-404, and GP276-286 (Fig. 2). When the synthetic
peptides were chromatographed under the same condi-
tions, the peptides were found to coelute with their corre-
sponding active fractions (data not shown), thus confirming
that each peptide is naturally presented in LCMV-infected
cells. Neither CTL line recognized fractions derived from
uninfected MC57 cells (data not shown). Each peptide
fraction was also tested for its ability to sensitize target cells
to lysis using spleen cells isolated from mice that had been
infected 8 d before with LCMV-WE. Although LCMV-
specific lysis was not observed using fractions other than
those described above (data not shown), it remains possible
that other LCMV-derived peptide epitopes, present at a
copy number too low to detect from 10
 
9
 
 infected MC57
cells, are processed and presented. This experiment was
carried out on two separate occasions.
 
Quantitation of Peptides in Infected Cells.
 
To determine the
extraction efficiency of each of the three naturally processed
peptide epitopes, 109 uninfected MC57 cells were mixed
with 10 ng of each peptide immediately before extraction
and fractionation. Active fractions were identified as described
above for naturally processed LCMV peptides. Chromium
release assays were carried out whereby precisely quanti-
tated synthetic peptides were titrated in 10-fold dilutions in
the wells of round-bottomed 96-well plates (0.0002–2,000
pg peptide/well). Target cells, T2-Db, were added at 104
cells/well. Subsequently, CTL lines of corresponding pep-
tide specificity were added to each well and cytotoxic ac-
tivity was determined 5 h later. In the same assay, active
fractions containing admixed peptides were also titrated in
10-fold dilutions and tested for their ability to sensitize tar-
get cells, T2-Db, to lysis by the appropriate CTL line. Fig.
3 shows the titration curves generated using synthetic pep-
tides GP33-41 (A), GP276-286 (C), and NP396-404 (E)
Figure 2. Identification of naturally processed LCMV peptides from
infected MC57 cells. Active peptide fractions eluted from immunopuri-
fied Db molecules from LCMV-infected MC57 cells were identified using
polyclonal CTL lines. Dilutions of each peptide fraction were incubated
with target cells, T2-Db, and tested for their ability to sensitize polyclonal
CTL lines specific for peptides GP33-41, GP276-286, and NP396-404 to
lysis. Fractions eluted from glycine columns or from immunopurified Db
molecules from uninfected MC57 cells did not sensitize T2-Db cells to ly-
sis by the same CTL lines. CTL assays were carried out using an E/T ratio
of 5:1.
Figure 3. Quantitation of admixed synthetic peptides GP33-41,
GP276-286, and NP396-404. Synthetic peptides were incubated in ti-
trated concentrations with T2-Db target cells and tested for lysis by the
appropriate CTL line. In addition, between 0.0001 and 1% of the ad-
mixed synthetic peptides extracted from 109 uninfected MC57 cells were
incubated with T2-Db cells and tested simultaneously for lysis by the same
CTL lines. The amount of peptide recovered after the elution procedure
was determined by calculating the amount of peptide required for 40%
specific lysis (A and B, GP33-41), 20% specific lysis (C and D, GP276-
286), or 50% specific lysis (E and F, NP396-404). CTL assays were car-
ried out using an E/T ratio of 5:1.1651 Gallimore et al.
and the corresponding admixed peptide fractions (Fig. 3, B,
D, and F). By comparison of the titration curves, it was de-
termined that 0.6% of the GP33-41 active fraction con-
tained 10 pg of the peptide (Fig. 3, A and B), 0.13% of the
GP276-286 active fraction contained 5 pg of the peptide
(Fig. 3, C and D), and 0.0006% of the NP396-404 active
fraction contained 0.03 pg of the peptide (Fig. 3, E and F).
Thus, z1.7 ng of admixed peptide GP33-41, z3.8 ng of
admixed peptide GP276-286, and z5 ng of admixed peptide
NP396-404 were recovered after the peptide extraction
procedure. Since 10 ng of each peptide was initially used in
the spiking procedure, the binding plus extraction efficien-
cies for peptides GP33-41, GP276-286, and NP396-404
were thus estimated as 17, 38, and 50%, respectively.
After another round of restimulation, each peptide-spe-
cific CTL line was used to determine the amount of natu-
rally processed LCMV peptides eluted from virus-infected
MC57 cells. This analysis was carried out as described
above for the admixed synthetic peptides. Fig. 4, A and B
show that 4.4% of the GP33-41 active fraction contained
15 pg of the peptide. Similarly, Fig. 4, C and D show that
3.9 and 5.9% of the two GP276-286 active fractions con-
tained 1.5 pg of peptide each, whereas Fig. 4, E and F
show that 0.13 of the NP396-404 active fraction contained
0.2 pg of peptide. Thus, a total of 341, 64, and 154 pg of
peptides GP33-41, GP276-286, and NP396-404 was re-
covered, respectively, from 109 infected MC57 cells. By as-
suming the same recovery rate for admixed and naturally
processed peptides (17% for GP33-41, 38% for GP276-
286, and 50% for NP396-404), the amount of each natu-
rally processed peptide was calculated as 2 ng of GP33-41,
0.16 ng of GP276-286, and 0.3 ng of NP396-404. Since 1 ng
of peptide extracted from 109 cells corresponds to z540
molecules/cell, the amount of naturally processed peptide
recovered corresponds to 1,080 molecules of peptide GP33-
41, 162 molecules of peptide NP396-404, and 92 mole-
cules of peptide GP276-286 per cell.
Adoptive Transfer of CTL Lines in LCMV-infected Mice.
The CTL lines used in the experiments described above
were used in adoptive transfer experiments whereby ti-
trated numbers of each CTL line were injected intrave-
nously into mice that had been infected 5 h before with 20
PFU of LCMV. Viral titers were determined 4 d later. The
results, shown in Fig. 5, indicate that the protective capac-
ity of each CTL line was different. The NP396-specific
CTL line was most efficient at controlling infection with
LCMV, the GP276-specific line controlled the infection
with intermediate efficiency, and the GP33-specific line
was the least efficient. Similar results were obtained after
adoptive transfer of two other independently generated
CTL lines of each specificity (data not shown). The experi-
ment was repeated using mice that had been infected 48 h
before with LCMV to ascertain that the protective effects
observed in the above experiment were not due to an ear-
lier expression of the viral nucleoprotein than the viral gly-
coprotein (40). The results, shown in Fig. 6, indicate that
NP396-specific CTL were more protective than GP33-
specific CTLs, even at a time point when all viral gene
Figure 4. Quantitation of naturally processed peptides GP33-41,
GP276-286, and NP396-404. Synthetic peptides were incubated in ti-
trated concentrations with T2-Db target cells and tested for lysis by the
appropriate CTL line. In addition, between 0.001 and 10% of each active
peptide fraction recovered from 109 LCMV-infected MC57 cells were in-
cubated with T2-Db cells and tested simultaneously for lysis by the same
CTL lines. The amount of peptide recovered after the elution procedure
was determined by calculating the amount of peptide required for 20%
specific lysis (A and B, GP33-41), 15% specific lysis (C and D, GP276-
286), or 50% specific lysis (E and F, NP396-404). CTL assays were car-
ried out using an E/T ratio of 5:1.1652 Antiviral Protection by LCMV-specific Cytotoxic T Cells
products would be expected to be expressed within in-
fected cells. Thus, the qualitative hierarchy, as defined by
the ability of CTLs of each specificity to control LCMV in-
fection, is different from the quantitative hierarchy that was
determined by measuring the frequencies of CTLs gener-
ated in response to LCMV infection.
Expression of Cell-surface Molecules on GP33-, GP276-,
and NP396-specific CTL Lines. To exclude the possibility
that the different protective capacity of each CTL line was
not attributable to differences in the expression of cell-sur-
face markers known to be associated with memory T cells,
each line was compared for expression of the activation
markers CD44, CD69, and CD25 (IL-2R). In addition,
the cells were compared for the expression of TCR and the
lymphocyte homing receptor L-selectin (CD62L). The his-
tograms (Fig. 7) show that expression of CD44, CD69, and
CD25 were upregulated to the same extent in each CTL
line in comparison to naive CD81 cells taken from the
spleen of a C57BL/6 mouse. CD62L, which is expressed
on most naive CD81 cells, was reduced to the same degree
on each CTL line. Surface expression of TCRs was also
similar on each CTL line. Thus, the protective potential of
each CTL line was not attributable to differences in the ex-
pression of the cell-surface molecules described above.
Expression of IFN-g in GP33-, GP276-, and NP396-spe-
cific CTL Lines. To investigate the possible role of IFN-g
in the protective effects observed above, IFN-g production
by each CD81 CTL line was monitored after overnight in-
cubation of the T cells with LCMV-infected macrophages.
After permeabilization of the cells and subsequent staining
with an anti–IFN-g antibody, expression of IFN-g was
monitored by FACSÒ analysis. Fig. 8 shows that although
all three CTL lines expressed significant levels of IFN-g af-
ter stimulation with infected cells, the highest level of ex-
pression was observed using NP396-specific CTLs. The
same hierarchy was observed after measurement of IFN-g
in the supernatants of the cultures described above (data
not shown). Expression of IFN-g was barely detectable in
CD81 cells from the spleen of a naive mouse. To address
the role of IFN-g in vivo, each CTL line was adoptively
transferred as described above into IFN-gR2/2 mice. The
results (Fig. 9) show that the hierarchy, in terms of antiviral
protection, was the same. The NP396-specific CTL line
was the most protective, followed by the GP276-specific
line, and subsequently the GP33-specific line. These results
show that the protective capacity of NP396-specific CTLs
is not due to the production of IFN-g. Although the hier-
archy of protection was the same as that observed for wild-
type mice, the results show that LCMV-titers were, on the
whole, higher in IFN-gR2/2 mice, thus indicating a role
for IFN-g in the initial clearance of LCMV. It is not clear
from these experiments whether the results obtained reflect
a direct antiviral effect of IFN-g or indirect effects relating
to the inability of APCs to upregulate MHC class I expres-
sion in response to IFN-g. In the latter case, both the de-
velopment of the endogenous LCMV-specific CTL re-
sponse and recognition of infected APCs by the adoptively
transferred CTL would be impaired. Interestingly, the re-
duction in the protective capacity of each CTL line in
LCMV-infected IFN-gR2/2 mice was more pronounced
for the GP33- and GP276-specific CTL lines. Since these
CTL lines are less sensitive to antigen than the NP396-spe-
cific line, their ability to recognize infected target cells may
also be more sensitive to changes in the degree of antigen
presentation. Based on the results obtained in the adoptive
transfer experiments, it appears that the protective potential
of CTLs depends on the avidity of the interaction between
the CTLs and their target cells. Figs. 3 and 4 show that
NP396- and GP276-specific CTLs are z1,000 and z10
times more sensitive to antigen, respectively, than are
GP33-specific CTLs. The same hierarchy is seen when
peptide titration curves are generated using ex vivo CTLs
isolated during the primary phase of LCMV infection or in
secondary cultures after in vitro restimulation of spleen cells
Figure 6. Adoptive transfer of
GP33- and NP396-specific
CTL lines into C57BL/6 mice
infected 48 h before with
LCMV. C57BL/6 mice were in-
fected intravenously with 20
PFU LCMV-WE. 48 h later,
groups of three mice intrave-
nously received 2 3 106 NP396-
(open circles) or GP33- (open trian-
gles) specific CTLs. One group
of two mice received no CTLs
(open squares). Splenic virus titers
were evaluated 2 d later. Dashed
line, the limit of sensitivity of the
assay.
Figure 5. Adoptive transfer of GP33-, GP276-, and NP396-specific
CTL lines into LCMV-infected C57BL/6 mice. C57BL/6 mice were in-
fected intravenously with 20 PFU LCMV-WE. 6 h later, groups of three
mice received 2 3 106 (A), 2 3 105 (B), or 2 3 104 (C) NP396- (open cir-
cles), GP33- (open triangles), or GP276- (closed triangles) specific CTLs intra-
venously. One group of three mice received no CTLs (open squares).
Splenic virus titers were evaluated 4 d later. Dashed line, the limit of sensi-
tivity of the assay.1653 Gallimore et al.
from LCMV-immune mice (data not shown). As an addi-
tional test to determine the importance of avidity in the
protective potential of virus-specific CTLs, two peptide
GP33-specific CTL lines were generated using APCs
pulsed with different concentrations of peptide. One CTL
line was generated as described above, whereas the other
was generated by weekly restimulation with RMA-S cells
pulsed with 100 ml of peptide at a concentration of 1 mg/ml
for 1 h at 378C. As described previously by Alexander-
Miller et al. (41), this methodology resulted in a lower
avidity CTL line that required target cells to be pulsed with
higher concentrations of peptide for recognition than the
high-avidity CTL line of the same specificity (Fig. 10 A).
In addition, although the low-avidity CTL line recognized
LCMV-infected target cells less efficiently than the high-
avidity line (data not shown), both lines recognized target
cells pulsed with high concentrations of peptide (100–
1,000 nM) equally well (Fig. 10 A). Cell surface expression
of CD8 and TCR was comparable on both high- and low-
avidity CTL lines (data not shown). Upon adoptive transfer
of each type of CTL line into mice that had been infected 4 d
before with LCMV, the high-avidity CTL line was found
to be more protective than an equivalent number of the
low-avidity CTL line (Fig. 10 B). These data, therefore,
further support the hypothesis that the avidity of the inter-
action between CTLs and their target cells plays an impor-
tant role in determining the efficiency with which CTLs
can recognize and lyse their specific targets.
Discussion
We have confirmed, by elution of Db-binding peptides
from LCMV-infected cells, the identity of three previously
described CTL epitopes. Thus, two epitopes from the viral
glycoprotein are the 9-mer GP33-41 (KAVYNFATC) and
the 11-mer GP276-286 (SGVENPGGYCL), and one epitope
derived from the viral nucleoprotein is the 9-mer NP396-
404 (FQPQNGQFI). Two reports have shown that the
GP33 peptide can also be presented to CTL by the Kb mol-
ecule (42, 43). Since the presence of phenylalanine at posi-
tion 5 has been identified as an anchor residue for Kb-bind-
ing peptides, it is possible that the naturally processed
peptide is GP34-41. It would therefore be of interest to de-
termine the precise nature of this epitope as well as the na-
ture of the precursor peptide that is transported into the
ER for binding to both Db and Kb.
Quantitation of each peptide epitope revealed that
GP33-41 was present at Z1,000 copies/cell, NP396-404
was present at Z160 copies/cell, and GP276-286 was
present at Z90 copies/cell. We cannot, however, exclude
Figure 7. Surface expression of CD8, TCR, CD25, CD44, CD62L, and CD69 on GP33-, GP276-, and NP396-specific CTL lines. FACSÒ profiles
demonstrating expression of cell-surface molecules on the three different CTL lines are shown in B. Naive C57BL/6 CD81 splenic T cells were also
stained (A).
Figure 8. Intracellular staining of IFN-g in GP33-, GP276-, and
NP396-specific CTL lines. Expression of IFN-g was analyzed by flow cy-
tometry. CTL lines were incubated overnight with uninfected macro-
phages (A) or LCMV-infected macrophages (2:1 ratio of macrophages to
T cells) (B), permeabilized, and stained with anti–IFN-g antibodies. Na-
ive C57BL/6 CD81 splenic T cells were also stained.1654 Antiviral Protection by LCMV-specific Cytotoxic T Cells
the possibility that differential regulation of viral gene ex-
pression might occur in different cell types or that different
amounts of the viral NP or GP are produced at different
stages in the viral life cycle. Nevertheless, the relative den-
sity of each antigen corresponds to the relative magnitude
of each CTL response stimulated after infection with virus.
Interestingly, the relative antigen densities also correlate
with the degree of TCR Vb usage observed after staining
the polyclonal CTL lines used in this study with a panel of
anti-Vb antibody supernatants. Expansions of Vb7, Vb6,
and Vb8 were observed in four GP33-specific lines, expan-
sions of Vb6 and Vb9 were observed in four NP396-spe-
cific lines, but an expansion of Vb10 only was observed in
each of four GP276-specific lines (data not shown). This
highly restricted TCR V gene usage has been described
previously for GP276-specific CTLs cloned from the
spleens of LCMV-infected mice (44).
Elution and subsequent quantitation of peptides from
cells infected with EBV and HIV have produced similar es-
timates of peptide abundance (8–1,300 molecules/cell; ref-
erences 45, 46). In both cases, the relative abundance of
peptide epitopes recovered was shown to correlate with the
magnitude of the CTL response. When three peptide
epitopes were eluted from cells infected with the bacterium
Listeria monocytogenes, a reciprocal relationship was found
between their relative abundance and the magnitude of the
CTL responses (47, 48). This observation has been attrib-
uted in part to the short half-life of the most abundant pep-
tide epitope, which could limit its capacity to activate T
cells. It is also possible that since the per cell copy number
of each peptide was rather high (800, 3,000, and 10,000)
compared with the relatively lower estimates of viral pep-
tide copy numbers, the density of each complex is well
over the threshold required for T cell activation and their
immunogenicity might be limited by other factors such as
the availability of T cells with appropriate TCRs. Studies
by Harding et al. (49) and Demotz et al. (50) have shown
that between 100 and 400 class II–peptide complexes are
required to stimulate proliferation of CD41 T cell hybrido-
mas. Similar studies that have quantitated the number of
class I–peptide complexes that are needed for recognition
and lysis of target cells by CTLs have shown that as few as
one molecule can be sufficient for lysis (51). Since the mea-
surements described above have used either T cell hybrido-
mas, T cell clones, or polyclonal T cell lines, it is not
known if such low ligand densities would be sufficient for
Figure 9. Adoptive transfer of GP33-, GP276-, and NP396-specific
CTL lines into LCMV-infected wild-type 129 (left) and IFN-gR2/2 mice
(right). Mice were infected intravenously with 20 PFU LCMV-WE. 6 h
later, groups of two mice received intravenously 2 3 106 (A), 2 3 105
(B), or 2 3 104 (C) of NP396- (open circles), GP33- (open triangles), or
GP276- (closed triangles) specific CTLs. One group of two mice received
no CTLs (open squares). Splenic virus titers were evaluated 4 d later.
Dashed line, the limit of sensitivity of the assay.
Figure 10. Recognition of peptide-pulsed target cells by two GP33-
specific CTL lines of different avidities and adoptive transfer of each CTL
line into LCMV-infected B6 mice. (A) Both high- (open triangles) and
low- (closed triangles) avidity GP33-specific CTL lines were tested for cy-
totoxicity against unpulsed T2-Db cells pulsed with titrated concentra-
tions of peptide GP33-41. (B) Mice were infected intravenously with 20
PFU LCMV-WE. 6 h later, groups of two mice received intravenously 2 3
106 (open triangles) or 2 3 105 (open circles) of the high-avidity GP33-spe-
cific CTL line or 2 3 106 (closed triangles) or 2 3 105 of the low-avidity
(closed circles) GP33-specific CTL line. One group of two mice received
no CTLs (open squares). Splenic virus titers were evaluated 4 d later.
Dashed line, the limit of sensitivity of the assay.1655 Gallimore et al.
the activation of naive CTLs. Memory CTLs, possibly
through the upregulation of costimulatory and adhesion
molecules (52, 53), are able to respond to lower concentra-
tions of antigen than primary effector cells. Whether this
means that the number of ligands required for the stimula-
tion of naive T cells is even higher remains unproven. The
low density of peptide ligands estimated to be present in
the virus-infected cells described above may argue against
this hypothesis. In addition, a study by Malarkannan et al.
has shown that a self-peptide recognized by alloreactive
CTLs can be present at ,10 copies/cell (54). Several re-
cent papers have shown that encounter with MHC–pep-
tide complexes results in serial downregulation of specific
TCRs (55–57). This observation has been attributed to the
very fast off-rate of the MHC 1 peptide–TCR interaction
so that after disengagement, the MHC–peptide complex
would be free to engage with other TCRs. It has been pro-
posed that through the serial triggering of TCRs, very few
MHC–peptide complexes would be required to sustain the
correct signals that a T cell must receive in order for activa-
tion to occur.
The results presented in this study also show that the im-
munogenicities of CTL epitopes, determined by both ex
vivo and in vitro analyses of peptide-specific CTL re-
sponses generated in LCMV-infected mice, do not corre-
late with the protective capacities of the different T cell
specificities (summarized in Table 1). The protective ca-
pacity of the CTLs described here do, however, correlate
with how little antigen CTLs require for recognition of
LCMV-infected cells. The difference between quantitative
and qualitative characteristics of CTLs may impinge upon
the success of antiviral therapies using adoptively trans-
ferred CTLs.
Table 1. Magnitude and Protective Capacity of H-2 Db–restricted CTLs Specific for LCMV Peptides NP396-404, GP33-41, and
GP276-286
Characteristics of LCMV-specific CTLs Hierarchy
Peptide density on infected MC57 cells GP33-41 . NP396-404 . GP276-286
Magnitude of CTL activity stimulated by LCMV infection GP33-41 . NP396-404 . GP276-286
Protective capacity of peptide-specific CTLs in C57BL/6 mice NP396-404 . GP276-286 . GP33-41
Protective capacity of peptide-specific CTLs in IFN-gR2/2 Mice NP396-404 . GP33-41 $ GP276-286
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